Tag: pharmaceuticals
-
Trial Shows No Difference in Drugs for Macular Degeneration
Researchers from the Boston University School of Medicine and the Veterans Affairs Boston Healthcare System in Jamaica Plain, Massacusetts have conducted a study that failed to show a difference in efficacy between the existing commercial drugs bevacizumab (Avastin) and ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears in the…
-
Trial Shows Genital Herpes Vaccine Ineffective for Women
The National Institute of Allergy and Infectious Diseases (NIAID), part of National Institutes of Health in Bethesda, Maryland, reports that an experimental vaccine to prevent genital herpes disease in women, proved ineffective when tested in a recently concluded clinical trial. GlaxoSmithKline (GSK) Biologicals, based in Belgium, developed the vaccine it calls Simplirix. GSK announced today…
-
Sanofi-aventis, Covance to Partner on Drug Development
Covance Inc., a drug development services company in Princeton, New Jersey, announced today an agreement with French pharmaceutical company Sanofi-aventis to provide drug development services to Sanofi-aventis over the next 10 years, with payments ranging from $1.2 billion to $2.2 billion. As part of the agreement, Sanofi-aventis will sell its Porcheville, France and Alnwick, United…
-
Process Validated for Purifying Protein-Based Drugs
Scientists at Rensselaer Polytechnic Institute in Troy, New York, are using nuclear magnetic resonance to understand and improve the process of purifying drugs that use proteins, which are notoriously difficult to separate from other potentially deadly impurities. A team led by Steven Cramer, professor of polymer engineering at Rensselaer studied the process of multimodal chromatography…
-
Korea Boosts R&D Budget, Targets Economic Growth
The Korea Herald newspaper reports today that the Korean government plans to increase the budget for its Ministry of Knowledge Economy by 7 percent in 2011 to KRW 4.5 trillion (USD 3.9 billion), with most of the funds going to research and development that benefits sustainable economic growth. The plans released today show substantial increases…
-
Trial Shows Positive Results for Hodgkin Lymphoma Drug
Seattle Genetics Inc., a biotech company in Bothell, Washington, and and Millennium, a developer of cancer drugs in Cambridge, Massachusetts, today released positive top-line results from a trial of their drug brentuximab vedotin. The drug is antibody-drug conjugate that works like an antibody carrying molecules toxic to cancer cells, targeted to CD30, a marker for…
-
FDA Gives Muscular Dystrophy Therapy Orphan Drug Status
Amsterdam Molecular Therapeutics (AMT), a biotechnology company in the Netherlands doing work in human gene therapy, said today that the U.S. Food and Drug Administration (FDA) has designated its gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, a committee the European Medicines Agency also granted the therapy, known as…
-
Clinical Trial Shows Results for Rheumatoid Arthritis Drug
A six-month clinical trial of the drug fostamatinib, developed by Rigel Pharmaceuticals of South San Francisco, California, shows improved outcomes for patients with rheumatoid arthritis (RA) who responded inadequately to ongoing treatment with another RA drug, methotrexate. Fostamatinib is an inhibitor of spleen tyrosine kinase, a modulator of immune signaling. The double-blind, placebo-controlled phase 2…
-
FDA Approves Novartis Multiple Sclerosis Drug
Novartis, an international pharmaceutical company, said today that the U.S. Food and Drug Administration (FDA) approved its drug Gilenya, an oral multiple sclerosis (MS) treatment. Gilenya (fingolimod) is the first drug available in the U.S. that treats relapsing forms of multiple sclerosis, the most common forms of the disease. Novartis says the Gilenya approval was…
-
NIH Awards Two Small Business Grants for Skin Disorders
Signum Biosciences Inc. in Princeton, New Jersey received two Small Business Innovation Research (SBIR) Phase 1 grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a division of the NIH, totaling over $684,000 for development of G-protein coupled receptor modulating therapeutics designed to treat common skin disorders. Phase 1 SBIR grants fund…